2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Adverse Events, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

3397 AXL/MER/CSF1R inhibitor adrexitinib with azacitidine and venetoclax for relapsed or refractory acute myeloid leukemia: Results from a phase I dose-escalation trial

Georgio Medawar, MD, Yesid Alvarado Valero, MD2, Naval Daver, MD3, Farhad Ravandi, MD4, Courtney DiNardo, MD, MSCE5, Nicholas Short, MD6, Alexandre Bazinet, MD, MSc7, Wei Ying Jen, BM BCh, FRCPath8, Tapan Kadia I, MD9, Eitan Kugler, MD PhD10, Naveen Pemmaraju, MD11, Angela C Burney12, Duyen Nguyen13, Allison Pike14, Jinho Choi15, Kiyean Nam, PhD16, Yoonji Lee17, Sean M Post18, Gautam Borthakur, MD19, Abhishek Maiti, MBBS20
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 Qurient Co., Ltd, Seongnam-si, Korea, Rep. of South
16 Qurient Co., Ltd, Seongnam-si, Korea, Rep. of South
17 Qurient Co., Ltd, Seongnam-si, Korea, Rep. of South
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background: Relapsed or refractory (R/R) acute myeloid leukemia (AML) has dismal outcomes. AXL, MER and CSF1R are receptor tyrosine kinases are expressed on leukemic blasts and in the marrow microenvironment, and their expression correlates with inferior prognosis and resistance to venetoclax. AXL/MER inhibition has shown synergy in combination with venetoclax in preclinical models. Similarly, CSF1R inhibition drives macrophage mediated anti-leukemia immune response in AML xenografts. Adrexitinib (Q702) is an oral, inhibitor of AXL/MER and CSF1R that has been shown to be safe and active in solid tumors. We hypothesized that combining adrexitinib with azacitidine and venetoclax (Aza/Ven) will be safe and active in AML. We here in report the results from a dose escalation trial of this triplet in R/R AML.

Methods: This investigator-initiated, phase I study enrolled adults with R/R AML or myelodysplastic syndrome (MDS)/AML (NCT06445907). Patients with uncontrolled infections, comorbidities or CNS leukemia were ineligible. Dose escalation of Q702 followed a BOIN design from  60 to 120 mg, administered orally on a week on/week off schedule during each 28-day cycle. Aza/Ven was administered as standard per USPI. Primary objective was safety/tolerability; secondary objectives included preliminary efficacy and survival. Exploratory objectives included assessment of PK/PD and correlatives.

Results: We enrolled 17 pts with a median age of 67 years (range 47-76) who had received a median of 3 prior lines of therapy (range 1-7) and prior venetoclax exposure in 82% pts. Median bone marrow blasts was 21% (range 4-95%), 40% had complex karyotype, 29% had TP53mut, and 12% had MECOM rearrangement.

The 30-day mortality was 0%. The most common adverse events of any grade were aspartate aminotransferase (AST) elevation (65%), hypokalemia (53%), and alanine aminotransferase (ALT) elevation (%) with most frequent grade 3/4 treatment-emergent adverse events (TEAE) being infections (58%), febrile neutropenia (35%), and AST elevation (17%). There were no treatment-related deaths. Adrexitinib 120 mg one week on/one week off with standard dose of Aza/Ven was established as the RP2D.

The objective response rate (ORR) was 29% (5/17), including CR with incomplete hematologic recovery (CRi) in 24% (n=4) and morphologic leukemia-free state in 6% (n=1). There was another pt with BM aplasia at dose level 1, considered a dose-limiting toxicity.  Median time to best response was 1 cycle (range 1-3). Among the 5 responders, 3 relapsed (with median time to relapse of 2 months), 2 proceeded to allogeneic transplant, and 1 received donor lymphocyte infusion. The median for the whole cohort OS was 5.5 months (95% CI 2.2-6.3) and median RFS for responders was 5.0 months (95% CI 1.9-NR).

Systemic exposure of Q702 and its active metabolites demonstrated dose dependency from the 60 to 120 mg dose. No significant change of exposure from Q702 monotherapy was observed when combined with Aza/Ven. Ongoing single-cell proteomic profiling by CyTOF will help dissect the mechanistic consequences of combined AXL/MER/CSF1R inhibition in AML and will be reported at the meeting.

Conclusion: AXL/MER/CSF1R inhibition with adrexitinib plus Aza/Ven was safe and showed encouraging preliminary activity in a high risk, heavily pretreated, Ven-refractory AML population. AST elevation was the most frequent TEAE was manageable without treatment discontinuation. These findings show adrexitinib with Aza/Ven to be a safe and potent triplet combination. Trial is planned for activation of frontline and salvage expansion cohorts.

Georgio Medawar, MD: No relevant conflicts of interest to declare.